MY17
Product Specifications
UNSPSC Description
MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC50=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes[1].
Target Antigen
Phosphatase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/my17.html
Smiles
O=C(NC/1=O)SC1=C\C2=CC=C(C=C2)C(NC3=NN=C(S3)SCC4=CC=C(C=C4)C#N)=O
Molecular Weight
479.55
References & Citations
[1]Li M, et al. Identification of 1, 3, 4-Thiadiazolyl-Containing Thiazolidine-2, 4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity[J]. Journal of Medicinal Chemistry, 2024.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-162499/MY17-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-162499/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
